Author

J. Gutiérrez

Observed names: J. Gutierrez, J.J Gutiérrez

Institution: Clínica Las Condes

Observed institutions: Peter MacCallum Cancer Centre, University Hospital of Bern, Institut Jules Bordet, Hospital Universitari Arnau de Vilanova, Sanofi (France), Clínica Las Condes, Breast Cancer Trials, International Drug Development Institute (Belgium), Dana-Farber Cancer Institute, National Institute of Oncology, Danish Breast Cancer Cooperative Group, Linköping University Hospital, Hospital Universitari Germans Trias i Pujol, Austrian Breast & Colorectal Cancer Study Group, International Breast Cancer Study Group, GEICAM – Spanish Breast Cancer Group, Hospital of Prato, European Institute of Oncology

OpenAlex ID: A5046064675

Adjuvant Chemotherapy With Sequential or Concurrent Anthracycline and Docetaxel: Breast International Group 02 98 Randomized Trial

2008 · P. Francis, J. Crown, et al. · JNCI Journal of the National Cancer Institute · 153

Overall Survival Benefit for Sequential Doxorubicin-Docetaxel Compared to Concomitant Doxorubicin and Docetaxel in Node-Positive Breast Cancer. 8-Yr. Results of the Breast International Group (BIG) 2-98 Phase III Adjuvant Trial.

2009 · A. Di Leo, P. Francis, et al. · Cancer Research · 6

Transitional cell carcinoma of the ovary

2005 · R. Yazigi, S. Sahid, et al. · Journal of Obstetrics and Gynaecology · 6

Anthracyclines: is more, better and/or more dangerous?

2003 · R. Arriagada, J. Gutiérrez · Annals of Oncology · 4

Correlation of outcome of resected non-small-cell lung cancer (NSCLC) with p53 mutations detected by yeast functional assay

2000 · M Monzó, A O'Brate, et al. · Lung Cancer · 2

P-191 Induction chemotherapy (CT) followed by acceleratedradiotherapy and concurrent cisplatin in locally advanced non-small cell lung cancer (NSCLC)

2005 · R. Arriagada, S. Kleinman, et al. · Lung Cancer

Works count: 6

Citation count: 171

H-index: 4

I10-index: 1